AMSF Earnings

AMSF reported its FY2025Q4 earnings on 2026-02-25, showcasing a revenue of 0.00 against an estimate of 80.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.57 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following AMSF's FY2025Q4 earnings announcement on 2026-02-25, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, AMSF's stock price tends to shift by an average of -2.12% in the 10 days leading up to earnings and +0.61% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AMSF’s annual revenue to reach 80.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.09% and EPS estimates Revise Downward by -0.32% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AMSF's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.09%, while EPS estimates moved Revise Downward by -0.32% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AMSF's stock price typically moves by -2.12% in the 10 days before its earnings and +0.61% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 80.00M.

The earnings call presents a mixed picture: strong underwriting and policyholder retention, but slight decreases in net income and investment income. The Q&A reveals confidence in growth strategy and stable competitive landscape, but concerns about medical inflation and large losses persist. Despite a positive book value increase, no new partnerships or significant guidance changes were announced. The market's competitive nature and lack of immediate expansion plans further balance the sentiment. Given these factors, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment rating.